Envision offers a non-drug therapy to improve your patient's vision and quality of life!
INMODE'S NON-SURGICAL ALTERNATIVE TO TREAT THE CAUSE OF DRY EYE
Envision is the new in-office standard revolutionising ocular care procedures for the treatment of meibomian gland dysfunction (MGD) and the symptoms of dry eye disease (DED).
Morpheus8 delivers the deepest fractional treatments available, penetrating subdermal tissue up to 8mm (7mm + 1mm thermal profile).
This ground breaking, non-surgical ophthalmic device, deploys multiple programmable modalities which work synergistically to deliver precision ocular treatments.
Four fractional tips with different microneedle configurations for customised treatments (Prime 12 pin, Resurfacing 24 pin, Morpheus8 24 pin, and Body 40 pin) deliver clinically proven RF energy to multiple treatment depths (0.5mm – 7mm).
Envision’s small-size, bipolar radiofrequency (RF) and Intense Pulsed Light (IPL) applicators with precise depth control allowing for highly efficacious procedures in the small, more delicate subdermal layers of the periorbital region.
Equipped with Burst mode RF technology, Morpheus8 Body automatically deploys bipolar RF energy to multi-level treatment depths in a single cycle. The ability to target tissue sequentially at three levels, in millisecond intervals, allows for a significant reduction in treatment times, minimizes skin injury, increases treatment uniformity, and enables customized full body fractional procedures.
The Morpheus8 Prime fractional radio-frequency microneedling technology allows for droopy eyelids to be tightened.
Equipped with Burst mode RF technology, Morpheus8 Body automatically deploys bipolar RF energy to multi-level treatment depths in a single cycle. The ability to target tissue sequentially at three levels, in millisecond intervals, allows for a significant reduction in treatment times, minimizes skin injury, increases treatment uniformity, and enables customized full body fractional procedures.
TECHNOLOGIES INCLUDED
Forma-I (bipolar radiofrequency) addresses the symptoms of dry eye disease (DED) caused by Meibomian Gland Dysfunction (MGD). Intended for use in the the periorbital area and upper and lower lids and relieves inflammation of meibomian glands and eye irritation.
Lumecca-I is an effective treatment of benign pigmented epidermal lesions and benign cutaneous vascular lesions.Lumecca was developed with an advanced xenon flash lamp producing 40% of total pulse energy in the 500-600 nm range. IPL energy penetrates the skin and is selectively absorbed by lesion chromophores (melanin or hemoglobin).
Morpheus8 is a minimally invasive fractional technology for dermatological and general surgical procedures for electrocoagulation and hemostasis. It is a clinically proven fractional technology
designed to treat tissue. RF energy is delivered to multiple treatment depths through bipolar arrays of microneedles and results in localised heating and coagulation of tissue.
BEFORE & AFTERS
PEER REVIEWED ARTICLE
Transcutaneous Radiofrequency-mediated Meibomian Gland Expression is an Effective Treatment for Dry Eye: A Prospective Cohort TrialText
ENVISION PRODUCT BROCHURE
CONTACT US!
Contact us today to learn more about our portfolio of tips and learn how to make the most of Morpheus8 treatment.
InMode connects medical and non-medical professionals to the latest technologies that can optimise results for their patients and their clinics. Our non-invasive and minimally invasive technologies provide solutions for body contouring, skin rejuvenation, hair removal, anti-ageing, women’s health and wellness, pigment and vascular lesions. With over 60+ peer reviewed clinical publications, InMode technologies are a proven to provide real, repeatable and consistent results.
Are you a provider?
BE INSPIRED. BE INFORMED. BE INMODE
Our mission is to deliver in our promise! Create innovative, life changing technology that leads the industry in enhancing beauty and well-being.